We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » European Commission Approves Six Additional Indications for Merck’s Keytruda
The item has been added to your shopping cart.
European Commission Approves Six Additional Indications for Merck’s Keytruda
The European Commission has approved Merck’s blockbuster oncology drug Keytruda (pembrolizumab) for six new indications, including persistent, recurrent or metastatic cervical cancer.